SARS News and Research

RSS

About 84% of antibodies in plasma target non-RBD epitopes on SARS-CoV-2 spike protein, finds study

In a new study recently published in the journal Science, a team of researchers in the U.S. found that most of the antibodies circulating in the blood target areas of the viral spike protein outside the receptor-binding domain (RBD), the part of the spike that binds directly to human cell receptors.

6 May 2021

Researchers develop a multivalent vaccine for COVID-19 and influenza

Researchers at Duke University, USA, are looking into the possibility of a combined influenza and COVID-19 vaccine that could be used to simultaneously protect against annual flu strains and the SARS-CoV-2. Preclinical results showed the vaccine protected mice from both SARS-CoV-2 and the flu.

6 May 2021

Research shows how the world’s population has created an ideal breeding ground for infectious diseases

The way that many of us live has created the “perfect storm” for the evolution and transmission of infectious diseases like Covid-19 according to a researcher at the University of East Anglia.

6 May 2021

Study finds no evidence of increased risk for COVID-19 from aspirin/NSAID use

At the beginning of the pandemic, there were concerns over the use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), increasing the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. NSAIDs are commonly used to treat SARS-CoV-2 infection-related symptoms such as flu and cough and are frequently taken by older adults with multiple health conditions.

6 May 2021

Monocytes promote viral control during SARS-COV-2 infection

In a paper recently uploaded to the preprint server bioRxiv by Vanderheiden et al. (May 4th, 2021) the contribution of monocytes in promoting protective immunity from SARS-CoV-2 is investigated in a murine model, suggesting that CCR2 plays the role of an inflammation modulator in early infection.

6 May 2021

Study: Second vaccine dose still makes organ transplant recipients vulnerable to COVID-19

In a study published today in the Journal of the American Medical Association (JAMA), Johns Hopkins Medicine researchers show that although two doses of a vaccine against SARS-CoV-2 - the virus that causes COVID 19 - confers some protection for people who have received solid organ transplants, it's still not enough to enable them to dispense with masks, physical distancing and other safety measures.

6 May 2021

FDA outlines inspectional activities during COVID-19 pandemic

Today, the U.S. Food and Drug Administration issued a new report titled, "Resiliency Roadmap for FDA Inspectional Oversight," outlining the agency's inspectional activities during the COVID-19 pandemic and its detailed plan to move toward a more consistent state of operations, including the FDA's priorities related to this work going forward.

6 May 2021

Researchers identify potent small molecule TMPRSS2 inhibitor against SARS-CoV-2

A team of scientists from the USA and Canada has recently identified and characterized a novel small-molecule compound inhibitor of cellular serine protease TMPRSS2, which shows significant antiviral potency against emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 May 2021

Novel pipeline identifies millions of molecular targets in SARS-CoV-2

Researchers in the United States have developed a novel pipeline for high-throughput, automated annotation of the genes, proteins and functional domains in the genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Prior MMR or Tdap vaccination may reduce risk of severe COVID-19

Researchers in the United States have shown that prior Measles-Mumps-Rubella (MMR) or Tetanus-Diphtheria-pertussis (Tdap) vaccination may reduce the risk of severe outcomes in patients with coronavirus disease 2019 (COVID-19).

5 May 2021

Repurposing an existing, cheap drug into long-acting injectable therapy to treat Covid-19

Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.

5 May 2021

Robust passive and active immunity found in infants born to COVID-19 positive mothers

A new study provides evidence that babies born to mothers who were COVID-19 positive two or more months before delivery are protected by maternal antibodies, besides mounting a robust immune response in case they contract the infection in the perinatal period.

5 May 2021

Pregnancy may increase the risk of COVID-19 severity

Against the background of the COVID-19 pandemic, the impact of SARS-CoV-2 infection in pregnancy has been a subject of much controversy. In order to help answer the question as to whether this infection causes significant harm in pregnancy, a new study, released as a medRxiv* preprint, reports on the disease outcomes of this infection in pregnant women.

5 May 2021

Women’s views on COVID-19 vaccination during pregnancy: A UK-based study

A new study, recently released as a preprint on the medRxiv* server, describes COVID-19 vaccine willingness among pregnant women in the UK.

5 May 2021

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Researchers have developed a promising new anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models.

5 May 2021

Mechano-immunological response to SARS-CoV-2

In a recent study, researchers demonstrated a human organ-on-a-chip (Organ Chip) microfluidic model of the lung alveolus (Alveolus Chip) - that recapitulates the human alveolar-capillary interface with an air-liquid interface (ALI) and vascular fluid flow to understand the local triggers in the lung in vitro.

5 May 2021

Stem cell therapy for COVID-19 and ARDS

In a review paper recently uploaded to the journal Biomedicine & Pharmacotherapy by Mahendiratta et al. (May 2021) the applicability of stem cells in treating severe SARS-CoV-2 infection is investigated, with regard to ARDS therapy.

5 May 2021

Pfizer/BioNTech and Moderna vaccines induce T-cell immunity against SARS-CoV-2

Researchers in the United States have shown that the Pfizer/BioNTech and Moderna messenger RNA (mRNA) vaccines are effective at generating T-cell immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 May 2021

Researchers perform a comprehensive analyses to clarify the origins of coronaviruses

Coronavirus (CoVs) infection in animals and humans is not new. The earliest papers in the scientific literature of coronavirus infection date to 1966. However, prior to SARS-CoV, MERS-CoV, and SARS-CoV-2, very little attention had been paid to coronaviruses.

5 May 2021

Pan-COVID-19 vaccine protects mice against SARS-CoV-2 variants

Researchers in the United States have identified short peptide sequences in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are immunogenic in a mouse model and may provide protection against viral variants.

5 May 2021